651 results on '"Witzens‐Harig, Mathias"'
Search Results
2. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
3. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
4. Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis
5. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
6. 1 Kardiologie und Angiologie Kardiologie Angiologie
7. 4 Gastroenterologie Gastroenterologie
8. 7 Nephrologie Nephrologie
9. 8 Wasser-, Elektrolyt- und Säure-Basen-Haushalt Wasser-, Elektrolyt- und Säure-Basen-Haushalt
10. 6 Endokrinologie und Stoffwechsel Endokrinologie
11. 13 Anhang
12. 10 Rheumatologie Rheumatologie
13. 3 Pneumologie Pneumologie
14. Vorwort
15. 2 Hämatologie Hämatologie
16. 9 Immunologie Immunologie
17. 12 Intensivtherapie Intensivtherapie
18. 5 Leber, Gallenblase, Pankreas Gallenblase Pankreas Leber
19. Sachverzeichnis
20. Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten
21. Ibrutinib
22. Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
23. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
24. Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection
25. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
26. Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation
27. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience
28. Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma
29. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma
30. Bone Marrow Harvesting of Allogeneic Donors in an Outpatient Setting: A Single-Center Experience
31. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
32. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial
33. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis:The UNFOLDER Study
34. Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma:Subgroup Analysis of the UNFOLDER Trial
35. Supplementary Table 1 from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
36. Data from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
37. Supplementary Table 2 from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
38. Supplementary Figures from CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
39. HCV load as a possible prognostic factor in patients with HCV-related DLBCL
40. The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin’s lymphomas
41. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas
42. Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
43. Ibrutinib
44. In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study
45. First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
46. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells
47. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
48. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma
49. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma
50. Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.